Modopar 125 (Benserazide Hydrochloride, Levodopa)

Levodopa acts as a precursor to dopamine. After oral administration, it crosses the blood‑brain barrier and is converted to dopamine by aromatic L‑amino acid decarboxylase within the central nervous system. Benserazide blocks this enzyme in the periphery, ensuring more levodopa reaches the brain where it restores dopaminergic neurotransmission.

The exact dose of Modopar 125 is individualized by the prescribing clinician based on disease severity, patient response and tolerability. Physicians typically start with a low dose and titrate upward to achieve optimal symptom control while monitoring for side effects.

Safety data for Modopar 125 in pregnancy and lactation are limited. The product is classified as pregnancy category unknown, and it should only be used if the potential benefit justifies the potential risk to the fetus or infant. Breastfeeding mothers should consult their healthcare provider before use.

To order Modopar 125, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, and will request verification of trade or institutional credentials. After confirmation, the team provides pricing, availability, shipping details and any necessary import documentation.

Modopar 125 combines levodopa with benserazide, a peripheral decarboxylase inhibitor, similar to other products such as Sinemet. Compared with dopamine agonists, levodopa‑based therapy generally offers stronger symptomatic relief but may be associated with motor complications over time. Choice of therapy depends on individual patient factors, disease stage and physician judgment.

Modopar 125 tablets should be stored at ambient temperature, below 25 °C, in the original container to protect them from moisture and light. Keep the product out of reach of children and avoid storing in humid or excessively hot environments.

Modopar 125 is taken orally with a full glass of water. It can be taken with or without food, although high‑protein meals may interfere with absorption. Tablets should be swallowed whole and not crushed or chewed unless specifically instructed by a healthcare professional.

Serious risks include dyskinesia (involuntary movements), severe orthostatic hypotension, psychiatric disturbances such as hallucinations, and rare events like neuroleptic malignant syndrome. Patients should report sudden changes in mood, uncontrolled movements, fainting episodes or any severe side effect to their physician promptly.

Modopar 125 is contraindicated in patients with known hypersensitivity to levodopa, benserazide or any excipients, as well as those with narrow‑angle glaucoma. Caution is advised for individuals with severe cardiovascular disease, hepatic impairment, or a history of malignant melanoma. The medication should be avoided in these populations unless a specialist determines that benefits outweigh risks.